Submission pursuant to Regulation 30 (LODR)Regulations, 2015- Press Release
WOCKPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Wockhardt reported strong turnaround with FY26 profit before tax of Rs. 238 crore compared to a loss of Rs. 16 crore in FY25. Q4FY26 revenue grew 30% year-on-year to Rs. 965 crore, while full-year revenue increased 11% to Rs. 3,373 crore. EBITDA margins expanded significantly from 13.8% to 18.7% for FY26. Exceptional items of Rs. 85 crore included one-time charges for restructuring, US entity liquidation, and settlement with Dr. Reddy's (net credit of Rs. 35.35 crore). Biotech operations delivered 27% growth reaching Rs. 697 crore for FY26, driven by Emerging Markets insulin segment.
Strong turnaround from losses to profitability with margin expansion signals operational efficiency gains. The stock could see positive sentiment given revenue growth and improved bottom-line performance.